{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-037609","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.531753+00:00","generated_at":"2026-06-04T06:07:34.281387+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CalciMedica reports FY2023 net loss $34.4M; cash $11.2M; CARPO topline data Q2 2024","bullets":["Cash, equivalents, and short-term investments $11.2M at Dec 31, 2023; pro forma after Jan 2024 private placement ~$25.5M, funding into 2H2025.","Net loss $34.4M ($7.66 per share) for FY2023; total operating expenses $38.1M including $16.2M one-time charges from reverse merger.","CARPO Phase 2b trial of Auxora in acute pancreatitis enrollment on track; topline data expected Q2 2024.","KOURAGE Phase 2 trial for severe AKI with AHRF cleared by FDA; first patient enrollment Q2 2024, data expected 2025.","CRSPA Phase 1/2 trial for asparaginase-induced pancreatic toxicity expanded to Phase 2; initial cohort data showed fewer hospital days."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-037609","json":"https://secwatch.observer/filing/0000950170-24-037609.json","markdown":"https://secwatch.observer/filing/0000950170-24-037609.md","text":"https://secwatch.observer/filing/0000950170-24-037609.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000095017024037609/0000950170-24-037609-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000095017024037609/calc-20240328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:07:34.281387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3552e9c8cd6fb521c34c4252ffa8629e7e6b14f9","claim":"CalciMedica, Inc. reported the year ended December 31, 2023 results: net income $34.4 million, or $7.66 per share (basic and diluted), EPS $7.66 per share (basic and diluted).","evidence_excerpt":"Net loss was $34.4 million, or $7.66 per share (basic and diluted) for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000095017024037609/0000950170-24-037609-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"$34.4 million, or $7.66 per share (basic and diluted)"},{"label":"EPS","value":"$7.66 per share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}